ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: L3

Classification Criteria for Systemic Sclerosis: Preliminary Results

Janet E. Pope1, Dinesh Khanna2, Jaap Fransen3, Sindhu R. Johnson4, Murray Baron5, Alan G. Tyndall6, Marco Matucci-Cerinic7, Raymond P. Naden8, Frank H.J. van den Hoogen9 and ACR/EULAR Classification Criteria for Systemic Sclerosis10, 1Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, 2Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 3Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4Dept of Rheumatology, Toronto Western and Mt. Sinai Hospitals, University of Toronto, Toronto, ON, Canada, 5Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 6Rheumatology, University of Basel, Basel, Switzerland, 7Department of Biomedicine & Division of Rheumatology AOUC, University of Florence, Florence, Italy, 8Auckland City Hospital, Auckland, New Zealand, Austria, 9Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, 10Janet Pope, London, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: ACR, classification criteria, scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: ACR Late-breaking Abstracts Poster Session

Session Type: Late-Breaking Abstracts

Background/Purpose: The existing 1980 classification criteria for systemic sclerosis (SSc) are suboptimal for patients with early SSc and some patients with limited cutaneous SSc (lcSSc) where an important subset do not meet those criteria. Therefore, a joint EULAR and ACR committee was established to develop new classification criteria for SSc. These results are preliminary and not yet approved by the organizational sponsors.

Methods: Delphi exercises and a nominal group technique were used to create a set of potential items for classification of SSc.  The validity of the 23 items was tested in existing databases of SSc cases and controls. Next, twenty cases were prospectively collected to represent the spectrum of SSc (low probability to high probability) which were ranked by SSc experts and conjoint analysis (1000 Minds®) was used to assign weights to the items. This resulted in 17 items clustered in 13 domains with weights for the importance of each item. For the classification algorithm, experts agreed that all patients with sclerodactyly and scleroderma skin involvement proximal to the MCPs were considered SSc; patients with skin involvement due another scleroderma-like disorder (e.g. scleromyxedema) were excluded. A provisional threshold was established to classify definite SSc based on the sum of weights of 17 items.  To test the provisional algorithm, data on the items were prospectively collected in cases and controls in North America and Europe. To refine the threshold, a subset of cases (n=25) within the range of borderline probability of SSc was selected from the collected data. Experts were then asked to determine whether each case had ‘definite SSc’ or not, leading to a new threshold. During a face-to-face meeting of the Steering Committee, the 17 items were reduced to 9 while maintaining adequate sensitivity and specificity, tested in a random sample of cases and controls of 100 from North America and 100 from Europe (derivation sample). Cases of SSc and mimickers were collected at several sites in NA and Europe where approximately half of SSc had early disease. Weights were simplified by dividing each weight by 5 and rounding to the nearest whole number. The data were then re-analyzed in the remaining cases and controls (validation set; n=405). 

Results: The table provides the final items with the proposed weights. Only the maximum score in each domain is counted. A cut-off of >= 9 (out of 19) had a sensitivity of 91% and specificity of 92% in the validation cohort (n=405). The sensitivity and specificity of the former 1980 ARA criteria in this database were 75% and 72%, respectively. 

Conclusion: The preliminary results of the classification criteria for SSc performed better than 1980 Preliminary ARA Criteria for SSc. These criteria can be endorsed for epidemiological studies and clinical trials after approval by ACR and EULAR.

Table Preliminary Classification Criteria for Systemic Sclerosis

These criteria are only applicable for patients where scleroderma-like disorders (such as eosinophilic fasciitis, scleromyxedema, nephrogenic systemic fibrosis, etc) have been excluded. Patients with another connective tissue disease can be classified as systemic sclerosis if they meet the proposed cut off. Patients with sclerodactyly with skin thickening extending proximal to the MCPs are classified as SSc and score is not needed.

Criteria Domain#

Sub-criteria

Weight

Skin thickening of the fingers


(count the higher of the two)

 

Puffy fingers


Whole Finger, distal to MCP

2


4

Finger tip lesions

(count the higher of the two)

Digital Tip Ulcers

Pitting Scars

 

2

3

 

Telangiectasia        

 

 

2

Abnormal nailfold capillaries

 

 

2

Lung Involvement

 Pulmonary arterial hypertension and/or Interstitial lung Disease

2

Raynaud’s phenomenon

 

 

3

Scleroderma related antibodies

 

 Any of anti-centromere, anti-topoisomeraseI [anti-ScL 70], anti-RNA polymerase III

3

*A total score of 9 or more is classified as systemic sclerosis

#Item should be scored as present if it has occurred at anytime during the course of their disease

 

TOTAL SCORE*:

 

Disclosure: This work was sponsored by ACR and EULAR but has not been endorsed and is preliminary.

 


Disclosure:

J. E. Pope,

Actelion and Pfizer,

2,

Actelion and Pfizer,

5;

D. Khanna,

Actelion, BMS, Gilead, Genentech, ISDIN, and United Therapeutics,

2,

Actelion, BMS, Gilead, Genentech, ISDIN, and United Therapeutics,

5,

Actelion, BMS, Gilead, Genentech, ISDIN, and United Therapeutics,

8;

J. Fransen,
None;

S. R. Johnson,
None;

M. Baron,
None;

A. G. Tyndall,
None;

M. Matucci-Cerinic,
None;

R. P. Naden,
None;

F. H. J. van den Hoogen,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/classification-criteria-for-systemic-sclerosis-preliminary-results/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology